Optimal systemic therapy for early breast cancer in women: A clinical practice guideline

Current Oncology

Volumn 22, Issue , 2015, Pages S67-S81

  Eisen, A ^a   Fletcher, G G ^b   Gandhi, S ^a   Mates, M ^c   Freedman, O C ^d   Dent, S F ^e   Trudeau, M E ^a   Bedard, P ^f   Califaretti, N ^g   Dhesy, B ^h   Dueck, D A ⁱ   Enright, K ^j   Glenns, V ^k   Hamm, C ^l   Madarnas, Y ^m   Rahim, Y ⁿ   Rask, S ^o   Robinson, A ^c   Spadafora, S ^p   Verma, S ^e   Younus, J ^k   more..

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c KINGSTON GENERAL HOSPITAL   (Canada)

^d Durham Regional Cancer Centre   (Canada)

^e OTTAWA REGIONAL CANCER CENTRE   (Canada)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g Grand River Regional Cancer Centre   (Canada)

^h JURAVINSKI CANCER CENTRE   (Canada)

ⁱ Northwestern Ontario Regional Cancer Centre   (Canada)

^j Peel Regional Cancer Program   (Canada)

^k Windsor Regional Cancer Centre ^*  (Canada)

^l Centre Regional De Cancerologie De Windsor   (Canada)

^m QUEEN S UNIVERSITY   (Canada)

ⁿ Southlake Regional Cancer Centre   (Canada)

^o Royal Victoria Hospital Barrie   (Canada)

^p Sault Area Hospitals   (Canada)

more..

Author keywords

Adjuvant systemic treatment; Chemotherapy; Consensus process; Early breast cancer; Endocrine therapy; HER2 targeted therapy; Treatment guidelines

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; KI 67 ANTIGEN; TAMOXIFEN; TAXANE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CHEMOTHERAPY; DISEASE FREE SURVIVAL; EARLY CANCER; HORMONAL THERAPY; HUMAN; LEUKEMIA; LYMPH VESSEL METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PUBLICATION; RECURRENCE RISK; SYSTEMATIC REVIEW; SYSTEMIC THERAPY;

EID: 84931009137     PISSN: 11980052     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2320     Document Type: Article

References (83)

1. Berry DA, Cronin KA, Plevritis SK, et al. on behalf of the Cancer Intervention and Surveillance Modeling Network (cisnet) collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92.
2. Eisen A, Srikanthan A, Yeung L, Iyer R, Trudeau M. Provincial variation in utilization of adjuvant chemotherapy regimens in early stage breast cancer: data from the Cancer Care Ontario New Drug Funding Program (ndfp) [abstract P3-12-1]. Cancer Res 2013;73:.
3. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-12.
4. Browman GP, Newman TE, Mohide EA, et al. Progress of clinical oncology guidelines development using the practice guidelines development cycle: the role of practitioner feedback. J Clin Oncol 1998;16:1226-31.
5. Eisen A, Fletcher GG, Gandhi S, et al. Optimal Systemic Therapy for Early Female Breast Cancer. Evidence-based series 1-21. Toronto, ON: Cancer Care Ontario; 2014. [Available online at: https://www.cancercare.on.ca/toolbox/qualityguide lines/diseasesite/breast-ebs; cited August 19, 2014]
6. Senkus E, Kyriakides S, Penault-Llorca F, et al. on behalf of the esmo Guidelines Working Group. Primary breast cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(suppl 6):vi7-23.
7. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Ver. 2.2013. Fort Washington, PA: nccn; 2013. [Current version available online at: http://www.nccn.org/professionals/ physician_gls/pdf/breast.pdf (free registration required); cited April 8, 2013]
8. Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: summary of the consensus discussion. Breast Care (Basel) 2011;6:136-41.
9. Davies C, Godwin J, Gray R, et al. on behalf of the Early Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84.
10. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95. [Erratum in: J Clin Oncol 2010;28:3543]
11. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:907-22. [Erratum in: Arch Pathol Lab Med 2010;134:1101]
12. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010;134:e48-72.
13. Hammond MEH, Hayes DF, Wolff AC, Mangu PB, Temin S. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 2010;6:195-7.
14. Trudeau ME, Pritchard KI, Chapman JA, et al. Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Res Treat 2005;89:35-45.
15. Song YJ, Shin SH, Cho JS, Park MH, Yoon JH, Jegal YJ. The role of lymphovascular invasion as a prognostic factor in patients with lymph node-positive operable invasive breast cancer. J Breast Cancer 2011;14:198-203.
16. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47.
17. Chang M, Ismaila N, Kamel-Reid S, et al. on behalf of the Molecular Oncology Advisory Committee. Comparison of Oncotype dx with Multi-Gene Profiling Assays (e.g., Mamma-Print, PAM50) and Other Tests (e.g., Adjuvant! Online, Ki-67 and IHC4) in Early-Stage Breast Cancer. Toronto, ON: Cancer Care Ontario; 2013. [Available online at: https://www.cancer care.on.ca/common/pages/UserFile.aspx?fileId=291504; cited May 22, 2014]
18. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
19. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a transatac study. J Clin Oncol 2010;28:1829-34.
20. Albain KS, Barlow WE, Shak S, et al. on behalf of the Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
21. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model Adjuvant! for early breast cancer. J Clin Oncol 2005;23:2716-25.
22. Campbell HE, Taylor MA, Harris AL, Gray AM. An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer 2009;101:1074-84.
23. Galimberti V, Cole BF, Zurrida S, et al. on behalf of the International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (ibcsg 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013;14:297-305.
24. Jafferbhoy S, McWilliams B. Clinical significance and management of sentinel node micrometastasis in invasive breast cancer. Clin Breast Cancer 2012;12:308-12.
25. Peto R, Davies C, Godwin J, et al. on behalf of the Early Breast Cancer Trialists' Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-44.
26. Coudert B, Campone M, Spielmann M, et al. Benefit of the sequential administration of docetaxel after standard fec regimen for node-positive breast cancer: long-term follow-up results of the fnclcc-pacs 01 trial [abstract 603]. Cancer Res 2009;69:.
27. Coudert B, Asselain B, Campone M, et al. on behalf of the unicancer Breast Group. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the unicancer-pacs01 trial. Oncologist 2012;17:900-9.
28. Trudeau M, Charbonneau F, Gelmon K, et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 2005;6:886-98.
29. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis. Breast Cancer Res Treat 2012;135:335-46.
30. Ladoire S, Mignot G, Dalban C, et al. Foxp3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase iii unicancer-pacs 01 trial. Ann Oncol 2012;23:2552-61.
31. Jacquemier J, Boher JM, Roche H, et al. Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the fnclcc-pacs 01 randomized trial. Breast Cancer Res 2011;13:R109. [Available online at: http://breast-cancer-research.com/content/13/6/ R109; cited March 13, 2012]
32. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for nodepositive breast cancer patients: the fnclcc pacs 01 trial. J Clin Oncol 2006;24:5664-71.
33. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-85. [Erratum in: J Clin Oncol 2008;26:2793]
34. Dumontet C, Krajewska M, Treilleux I, et al. bcirg 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res 2010;16:3988-97.
35. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the bcirg 001 trial. J Clin Oncol 2009;27:1168-76.
36. Martin M, Pienkowski T, Mackey J, et al. on behalf of the Breast Cancer International Research Group 001 investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13.
37. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-71. [Errata in: N Engl J Med 2009;360:1685 and N Engl J Med 2008;359:106]
38. Burnell M, Levine MN, Chapman JA, et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 2010;28:77-82.
39. Swain SM, Tang G, Geyer CE, et al. nsabp B-38: definitive analysis of a randomized adjuvant trial comparing dosedense (dd) ac→paclitaxel (p) plus gemcitabine (g) with dd ac→p and with docetaxel, doxorubicin, and cyclophosphamide (tac) in women with operable, node-positive breast cancer [abstract LBA1000]. J Clin Oncol 2012;30:. [Available online at: http://meetinglibrary.asco.org/content/98794-114; cited December 20, 2014]
40. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized finxx trial. J Clin Oncol 2012;30:11-18.
41. Muss HB, Berry DA, Cirrincione CT, et al. on behalf of the calgb investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009;360:2055-65. [Erratum in: N Engl J Med 2009;361:1714]
42. Castiglione-Gertsch M, O'Neill A, Price KN, et al. on behalf of the International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003;95:1833-46.
43. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1177-83.
44. Smith IE, Dowsett M, Yap YS, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006;24:2444-7.
45. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002;9:466-72.
46. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-70.
47. Braverman SA, Sawhney H, Tendler A, et al. Serum estradiol above the postmenopausal level after chemotherapy-induced amenorrhea in breast cancer patients. Therapy 2006;3:609-12.
48. Groom GV, Griffiths K. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 1976;70:421-8.
49. Davies C, Pan H, Godwin J, et al. on behalf of the Adjuvant Tamoxifen: Longer Against Shorter (atlas) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: atlas, a randomised trial. Lancet 2013;381:805-16. [Erratum in: Lancet 2013;381:804]
50. Gray RG, Rea D, Handley K, et al. Att om: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer [abstract 05]. J Clin Oncol 2013;31:. [Available online at: http://meetinglibrary. asco.org/content/112995-132; cited December 20, 2014]
51. Francis PA, Regan MM, Fleming GF, et al. on behalf of the soft investigators and the International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;:[Epub ahead of print].
52. Ribi K, Luo W, Bernhard J, et al. on behalf of the soft investigators and the International Breast Cancer Study Group. Patient-reported endocrine symptoms, sexual functioning and quality of life (qol) in the ibcsg soft trial: adjuvant treatment with tamoxifen (t) alone versus t plus ovarian function suppression (ofs) in premenopausal women with hormone receptor-positive (hr+) early breast cancer (bc) [abstract S3-09]. Presented at the 2014 San Antonio Breast Cancer Symposium; San Antonio, TX, U.S.A.; December 9-13, 2014. [Available online at: http://www.abstracts2view.com/sabcs14/ view.php?nu=SABCS13L_182; cited January 14, 2015]
53. Bernhard J, Luo W, Ribi K, et al. Patient-reported endocrine symptoms, sexual functioning, and quality of life (qol) in the ibcsg text and soft trials: adjuvant treatment with exemestane (e) plus ovarian function suppression (ofs) versus tamoxifen (t) plus ofs in premenopausal women with hormone receptorpositive (hr+) early breast cancer (bc) [abstract 557]. J Clin Oncol 2014;32:. [Available online at: http://meetinglibrary. asco.org/content/129713-144; cited January 18, 2015]
54. Tevaarwerk AJ, Wang M, Zhao F, et al. Phase iii comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (e-3193, int-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2014;32:3948-58.
55. Mulcahy N. Two major trials: ais work in premenopausal breast cancer too. New option for treatment of hormone-sensitive disease [online news article]. Medscape from WebMD; June 1, 2014. [Available online at: http://www.medscape.com/view article/826021; cited June 5, 2014]
56. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-18.
57. Delozier T, Switsers O, Genot JY, et al. Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (tam-02 trial). Ann Oncol 2000;11:515-19.
58. Veronesi A, Miolo G, Magri MD, et al. Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study. BMC Cancer 2010;10:205.
59. Perez EA, Romond EH, Suman VJ, et al. Four-year followup of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from ncctg N9831 and nsabp B-31. J Clin Oncol 2011;29:3366-73.
60. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
61. Slamon D, Eiermann W, Robert N, et al. on behalf of the BCIRG 006 investigators. Phase iii trial comparing ac-t with ac-th and with tch in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis [slide presentation]. Presented at the 2006 San Antonio Breast Cancer Symposium; San Antonio, TX, U.S.A.; December 14-17, 2006. [Available online at: http://www.cirg.org/html/images/ BCIRG006+2nd+Interim+Analysis.pdf; cited October 27, 2011]
62. Slamon D, Eiermann W, Robert N, et al. on behalf of the Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83.
63. Goldhirsch A, Piccart M, Procter M, et al. hera trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up [abstract LBA6_PR]. Ann Oncol 2012;23:ixe2. [Available online at: http://annonc.oxfordjournals.org/ content/23/suppl_9/ixe1.full.pdf+html?sid=e1381f2a-b04f-444b-9ec4-71ec98521b77; cited January 1, 2015]
64. Wolff AC, Hammond ME, Hicks DG, et al. on behalf of the American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014;138:241-56.
65. Wolff AC, Hammond ME, Hicks DG, et al. on behalf of the American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.
66. Sawaki M, Tokudome N, Mizuno T, et al. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [respect (n-sas BC07)]. Jpn J Clin Oncol 2011;41:709-12.
67. Perez EA, Jenkins RB, Dueck AC, et al. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol 2011;29:651-9.
68. Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the asco/ cap HER2-positivity criteria. J Natl Cancer Inst 2012;104:159-62.
69. Perez EA, Reinholz MM, Hillman DW, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010;28:4307-15.
70. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231-8.
71. Untch M, Gelber RD, Jackisch C, et al. on behalf of the hera study team. Estimating the magnitude of trastuzumab effects within patient subgroups in the hera trial. Ann Oncol 2008;19:1090-6.
72. Members of the Breast Cancer Disease Site Group. The Role of HER2/neu in Systemic and Radiation Therapy for Women with Breast Cancer. Evidence-based series 1-17 [archived 2011]. Toronto, ON: Cancer Care Ontario; 2012. [Available online at: https://www.cancercare.on.ca/common/pages/UserFile. aspx?fileId=13878; cited October 6, 2012]
73. Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (hera) trial. J Clin Oncol 2010;28:3422-8.
74. Dowsett M, Procter M, McCaskill-Stevens W, et al. Diseasefree survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the hera trial. J Clin Oncol 2009;27:2962-9.
75. European Society for Medical Oncology (esmo). phare trial results comparing 6 to 12 months of adjuvant trastuzumab in early breast cancer [online news article]. Viganello-Lugano, Switzerland: esmo; October 1, 2012. [Available online at: http://www.esmo.org/Conferences/Past-Conferences/ESMO-2012-Congress/News-Press-Releases/Congress-News/ PHARE-trial-results-comparing-6-to-12-months-of-adjuvanttrastuzumab-in-early-breast-cancer; cited October 11, 2012]
76. Pivot X, Romieu G, Bonnefoi H, et al. phare trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer [abstract LBA5_PR]. Ann Oncol 2012;23:ixe2. [Available online at: http://annonc.oxfordjournals.org/ content/23/suppl_9/ixe1.full.pdf+html?sid=e1381f2a-b04f-444b-9ec4-71ec98521b77; cited October 11, 2012]
77. Pivot X, Romieu G, Debled M, et al. on behalf of the phare trial investigators. 6 Months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (phare): a randomised phase 3 trial. Lancet Oncol 2013;14:741-8.
78. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the finher trial. J Clin Oncol 2009;27:5685-92.
79. Joensuu H, Sperinde J, Leinonen M, et al. Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol 2011;22:2007-13.
80. Sledge GW, O'Neill A, Thor A, et al. Adjuvant trastuzumab: long-term results of E2198 [abstract 2075]. Breast Cancer Res Treat 2006;100(suppl 1):S106.
81. Anderson BO. Context-relevant guidelines in cancer care: breast cancer early detection, diagnosis and treatment in low-and middle-income countries. In: Magrath I, ed. Cancer Control 2013: Cancer Care in Emerging Health Systems. Woodbridge, U.K.: Global Health Dynamics; 2013. [Available online at: http://cancercontrol.info/wp-content/ uploads/2014/08/cc2013_36-40-Benjamin-O-Anderson_2013. pdf; cited August 18, 2014]
82. Yip CH, Cazap E, Anderson BO, et al. Breast cancer management in middle-resource countries (mrcs): consensus statement from the Breast Health Global Initiative. Breast 2011;20(suppl 2):S12-19.
83. El Saghir NS, Adebamowo CA, Anderson BO, et al. Breast cancer management in low resource countries (lrcs): consensus statement from the Breast Health Global Initiative. Breast 2011;20(suppl 2):S3-11.